Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656252 · ClinicalTrials.gov registry record · Phase 1
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
A Phase 1 study, sponsored by PrECOG.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01656252 is a Phase 1 study that was terminated before completion, run by PrECOG. The registered enrollment target is 15 participants.
The verdict
NCT01656252, a Phase 1 study, was terminated before completion, sponsored by PrECOG.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding. Phase I will study the side effects, best dose and platelet effects of eltrombopag when given with consolidation chemotherapy. After the maximum safe and tolerated dose and schedule is found in Phase I, the study will proceed to Phase II. Phase II will confirm the dose and schedule of eltrombopag identified in Phase I that can increase platelet counts in patients receiving consolidation therapy.
Interventions
- DRUG Phase I- Cytarabine & Eltrombopag
- DRUG Phase II- Sequence A
- DRUG Phase II- Sequence B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656252
The ClinicalTrials.gov registry entry for NCT01656252 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Phase I- Cytarabine & Eltrombopag is the first listed.
NCT01656252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01656252 about?
NCT01656252 is a clinical study titled "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission". Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding. Phase I will study th...
What is the current status of trial NCT01656252?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01656252?
The interventions under investigation include: Phase I- Cytarabine & Eltrombopag (DRUG), Phase II- Sequence A (DRUG), Phase II- Sequence B (DRUG).
Who is sponsoring clinical trial NCT01656252?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.